A Comparative Study of the Effects of a Dipeptidyl Peptidase-IV Inhibitor and Sulfonylurea on Glucose Variability in Patients with Type 2 Diabetes with Inadequate Glycemic Control on Metformin
| العنوان: | A Comparative Study of the Effects of a Dipeptidyl Peptidase-IV Inhibitor and Sulfonylurea on Glucose Variability in Patients with Type 2 Diabetes with Inadequate Glycemic Control on Metformin |
|---|---|
| المؤلفون: | Jeong-Ah Shin, Seung-Hwan Lee, Eun-Sook Kim, Kun-Ho Yoon, Ho-Young Son, Hun-Sung Kim, Jae Hyoung Cho |
| المصدر: | Diabetes Technology & Therapeutics. 15:810-816 |
| بيانات النشر: | Mary Ann Liebert Inc, 2013. |
| سنة النشر: | 2013 |
| مصطلحات موضوعية: | Adult, Blood Glucose, Male, medicine.medical_specialty, endocrine system diseases, Endocrinology, Diabetes and Metabolism, Type 2 diabetes, Gastroenterology, Sitagliptin Phosphate, chemistry.chemical_compound, Endocrinology, Asian People, Double-Blind Method, Internal medicine, Diabetes mellitus, Republic of Korea, medicine, Humans, Hypoglycemic Agents, Prospective Studies, Glycemic, Glycated Hemoglobin, Dipeptidyl-Peptidase IV Inhibitors, business.industry, nutritional and metabolic diseases, Middle Aged, Triazoles, medicine.disease, Hypoglycemia, Metformin, Oxidative Stress, Medical Laboratory Technology, Glimepiride, Sulfonylurea Compounds, Treatment Outcome, Diabetes Mellitus, Type 2, chemistry, Pyrazines, Sitagliptin, Patient Compliance, Drug Therapy, Combination, Female, Glycated hemoglobin, business, Follow-Up Studies, medicine.drug |
| الوصف: | This study aimed to compare the effects of sitagliptin on glycemic change and 24-h blood glucose variability with those of the sulfonylurea glimepiride.A 4-week randomized double blind-labeled prospective design was used. We recruited 33 patients who had been treated with metformin for at least 2 months. Each participant prescribed with metformin was randomly assigned to either the sitagliptin (100 mg) or the glimepiride (2 mg) group. Continuous glucose monitoring (CGM) was used to monitor glycemic changes for 3 successive days in both groups at baseline and at the 4-week follow-up. Glycemic changes and glucose variability were obtained using CGM, and these data were averaged over all subjects.The comparison of glycated hemoglobin (HbA1c) between baseline and the 4-week follow-up showed that HbA1c was significantly reduced in the sitagliptin group (7.0 ± 0.5% to 6.6 ± 0.4%, P0.001) and the glimepiride group (7.3 ± 0.4% to 6.9 ± 0.4%, P0.001). The sitagliptin and glimepiride groups had similar HbA1c levels after 4 weeks, and there were no significant differences between the two groups. The mean amplitude of glycemic excursions (MAGE) decreased significantly in the sitagliptin group (4.9 ± 1.0 to 3.7 ± 0.9 mmol/L, P0.001), but no significant difference was observed in the glimepiride group (5.7 ± 1.5 to 5.0 ± 1.4 mmol/L, P=0.175). The SD and oxidative stress markers did not differ significantly between the two groups.When sitagliptin was combined with metformin, the patients showed much more efficient blood glucose controlling effects, not only the three indexes of fasting blood glucose, postprandial blood glucose, and glycated hemoglobin, but also MAGE. |
| تدمد: | 1557-8593 1520-9156 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e908594369dd2bca274c572f793c50a4Test https://doi.org/10.1089/dia.2013.0038Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....e908594369dd2bca274c572f793c50a4 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15578593 15209156 |
|---|